What are the indications, dosing regimen, monitoring parameters, and precautions for ursodiol (ursodeoxycholic acid)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ursodiol (Ursodeoxycholic Acid): Clinical Guide

Primary Indications

Ursodiol is first-line therapy for primary biliary cholangitis (PBC) at 13-15 mg/kg/day, where it improves transplant-free survival and delays histologic progression. 1

Established Indications:

Primary Biliary Cholangitis (PBC)

  • Dosing: 13-15 mg/kg/day divided in 2-3 doses 2, 3
  • Improves serum bilirubin, alkaline phosphatase, aminotransferases, cholesterol, and IgM levels 2
  • Delays histologic progression and improves transplant-free survival 1
  • Continue therapy even with persistent alkaline phosphatase elevation—survival benefits persist 1
  • Safe during pregnancy and breastfeeding; should be continued throughout pregnancy 4

Primary Sclerosing Cholangitis (PSC)

  • Dosing: 15-20 mg/kg/day 4
  • May improve serum liver tests and surrogate markers of prognosis
  • Critical caveat: High-dose UDCA (28-30 mg/kg/day) is contraindicated in PSC—associated with increased adverse events, higher rates of transplantation, and worse outcomes 5, 6
  • Safe during pregnancy; continue if already prescribed 4

Gallstone Dissolution

  • Dosing: 8-10 mg/kg/day in 2-3 divided doses 3
  • Patient selection criteria:
    • Radiolucent, noncalcified stones <20 mm diameter
    • Patients who are poor surgical candidates or refuse surgery
    • Floating/floatable stones (high cholesterol content) have 50% dissolution rate 3
    • Stones ≤5 mm: 81% complete dissolution rate 3
  • Monitor with ultrasound at 6-month intervals first year 3
  • If no partial dissolution by 12 months, discontinue—success unlikely 3
  • Stone recurrence: 30-50% within 2-5 years after dissolution 3

Gallstone Prevention During Rapid Weight Loss

  • Dosing: 600 mg/day (300 mg twice daily) 3
  • Indicated for obese patients undergoing rapid weight loss (e.g., bariatric surgery)
  • Reduces cholecystectomy and ERCP rates post-bariatric surgery 7

Intrahepatic Cholestasis of Pregnancy (ICP)

  • Improves maternal pruritus (modest effect) 4
  • Reduces spontaneous preterm birth risk in bile acids >40 μmol/L 4
  • May be protective against stillbirth 4
  • Safe during pregnancy and lactation 4

Dosing Regimens by Indication

Indication Dose Frequency Duration
PBC 13-15 mg/kg/day 2-3 divided doses Indefinite
PSC 15-20 mg/kg/day 2-3 divided doses Indefinite
Gallstone dissolution 8-10 mg/kg/day 2-3 divided doses Up to 24 months
Gallstone prevention 600 mg/day 300 mg twice daily During rapid weight loss period
ICP/Pruritus Start 10 mg/kg/day, increase to 20 mg/kg/day 2-3 divided doses Until delivery

Monitoring Parameters

For PBC/PSC:

  • Serum bilirubin, alkaline phosphatase, aminotransferases, cholesterol at baseline
  • Repeat liver biochemistries every 3-6 months initially, then every 6-12 months once stable
  • Monitor for symptom improvement (though UDCA does not significantly improve fatigue or pruritus in PBC) 2

For Gallstone Dissolution:

  • Ultrasound at 6-month intervals during first year 3
  • If partial dissolution seen, continue therapy and confirm complete dissolution with repeat ultrasound 1-3 months later 3
  • Discontinue if no partial dissolution by 12 months 3
  • Monitor for stone recurrence with serial ultrasounds after dissolution 3

For ICP:

  • Measure serum bile acids weekly from 32 weeks gestation 4
  • Bile acids >100 μmol/L: plan delivery at 35 weeks to reduce stillbirth risk 4

Critical Precautions and Contraindications

Absolute Contraindications:

  • Calcified gallstones (will not dissolve) 3
  • Complete biliary obstruction
  • Acute cholecystitis or cholangitis

Relative Contraindications/Warnings:

  • Do NOT use high-dose UDCA (>25 mg/kg/day) in PSC—associated with worse outcomes 5, 6
  • Gallbladder non-visualization during treatment predicts failure; discontinue therapy 3
  • Stones >20 mm rarely dissolve 3
  • Short bowel syndrome or resected terminal ileum reduces absorption and efficacy 8

Drug Interactions:

  • Separate from cholestyramine/colestipol by at least 4 hours—bile acid sequestrants bind UDCA and reduce absorption 4
  • Aluminum-based antacids may reduce UDCA absorption

Safety Profile

Common Side Effects:

  • Dose-dependent diarrhea (most common) 9
  • Nausea (18% report as barrier to compliance) 7
  • Generally well-tolerated with minimal serious adverse events 1

Pregnancy and Lactation:

  • FDA Category B (safe in pregnancy)
  • Strongly recommended to continue during pregnancy for PBC and PSC 4
  • Safe during breastfeeding 4

Vitamin K Monitoring:

  • Cholestasis and concurrent use of cholestyramine/rifampicin increase vitamin K deficiency risk
  • Correct vitamin K deficiency when present 4

Common Clinical Pitfalls

  1. Using high-dose UDCA in PSC: Doses >25 mg/kg/day worsen outcomes—stick to 15-20 mg/kg/day maximum 5, 6

  2. Discontinuing UDCA in pregnancy: This is a critical error—UDCA is safe and should be continued 4

  3. Expecting symptom improvement in PBC: UDCA improves biochemistry and histology but does not significantly improve fatigue or pruritus 2

  4. Stopping UDCA when alkaline phosphatase remains elevated: Continue therapy—survival benefits persist even without complete biochemical response 1

  5. Attempting gallstone dissolution beyond 12 months without partial response: Futile—discontinue if no partial dissolution by 1 year 3

  6. Co-administering with cholestyramine without time separation: Reduces UDCA absorption—separate by ≥4 hours 4

  7. Cost barriers: 45% of patients cite cost as compliance barrier 7—address affordability upfront

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.